StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a research report report published on Tuesday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Price Performance
Shares of NASDAQ EVOK opened at $4.51 on Tuesday. The stock has a market cap of $38.77 million, a PE ratio of -2.46 and a beta of 0.38. Evoke Pharma has a 1 year low of $3.54 and a 1 year high of $18.60. The firm has a fifty day moving average price of $5.07 and a 200-day moving average price of $5.92.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). The business had revenue of $2.55 million during the quarter. Evoke Pharma had a negative return on equity of 964.25% and a negative net margin of 86.74%.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Stories
- Five stocks we like better than Evoke Pharma
- Buy P&G Now, Before It Sets A New All-Time High
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- How to Buy Cheap Stocks Step by Step
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
